Aegon Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
20.3%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
$1.03next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Extraordinary General Meeting (EGM) to vote on US Redomiciliation | 31 Dec 2026 |
| Target Effective Date for Legal-Domicile Transition to Delaware | 1 Jan 2028 |
Monitoring Framework
Key Performance Indicators
Operating Capital Generation (OCG) before holding and funding expenses Annually1.3B
Free Cash Flow Annually829M
Operating Profit Annually1.7BTarget: Grow at around 5% annually through 2027
Watch Items
- US Redomiciliation and Legal Seat TransitionTrigger: Extraordinary General Meeting (EGM) approval in Q4 2026Action: Monitor shareholder voting outcomes, regulatory approvals, and implementation costs (estimated at EUR 350 million).
- UK Business Strategic Review and Potential DivestmentTrigger: Execution of the £2 billion sale agreement of Aegon UK to Standard Life plcAction: Track regulatory approvals, closing conditions, and the subsequent receipt of £750 million cash and 15.3% equity stake in Standard Life.
- Transition to US GAAP ReportingTrigger: Full-year 2027 financial results publicationAction: Ensure systems readiness and monitor reconciliation differences between IFRS and US GAAP.
Research as of 2 Sep 2026